carbon tetrachloride has been researched along with Cruveilhier-Baumgarten Syndrome in 89 studies
Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed)
tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.
Cruveilhier-Baumgarten Syndrome: Liver cirrhosis with intrahepatic portal obstruction, HYPERTENSION, and patent UMBILICAL VEINS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression." | 7.77 | Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011) |
| " This study was conducted to investigate any protective effect of early propranolol administration in the development and degree of esophageal varices in cirrhotic rats with portal hypertension." | 7.75 | Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats. ( Alatsakis, M; Ballas, KD; Marakis, GN; Pavlidis, TE; Psarras, K; Rafailidis, S; Sakantamis, AK; Tzioufa-Asimakopoulou, V, 2009) |
| "In conclusion, carvedilol may alleviate liver cirrhosis in rats by inhibiting HSC activation, proliferation, invasion and collagen synthesis." | 5.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Portal hypertension is triggered by vasodilation due to impaired contraction of extrahepatic vessels." | 5.35 | Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Trebicka, J, 2009) |
| " In carbon tetrachloride-induced micronodular cirrhosis, portal sinusoidal flow, which reaches liver parenchyma, is high, and this is more pronounced in the presence of ascites." | 4.81 | Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. ( Reichen, J; Sägesser, H; Van de Casteele, M; Zimmermann, H, 2001) |
| "The effect of systemic treatment with adipose tissue-derived MSCs, pre-differentiated into hepatocytic cells, was investigated in a rat model of liver cirrhosis induced by chronic inhalation of carbon tetrachloride." | 3.85 | Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cells. ( Brückner, S; Christ, B; Hempel, M; Roderfeld, M; Roeb, E; Schwill, F; Thonig, A; Zipprich, A, 2017) |
| "Droxidopa might be an effective therapeutic agent for hemodynamic and renal alterations of liver cirrhosis and should be tested in cirrhosis patients." | 3.78 | Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. ( Augustin, S; Brull, A; Coll, M; Esteban, R; Ezkurdia, N; Genescà, J; Guardia, J; Martell, M; Raurell, I; Rodriguez, S, 2012) |
| " NaHS protected liver function, attenuated liver fibrosis, inhibited inflammation, and reduced the portal pressure, evidenced by the alterations of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), hyaluronic acid (HA), albumin, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and soluble intercellular adhesion molecule (ICAM)-1, liver histology, hepatic hydroxyproline content and α-smooth muscle actin (SMA) expression." | 3.77 | Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. ( Dong, X; Jiang, H; Jiang, X; Kang, K; Kanwar, JR; Li, J; Pan, S; Qiao, H; Sun, X; Tan, G; Zhao, M, 2011) |
| " This study was conducted to investigate any protective effect of early propranolol administration in the development and degree of esophageal varices in cirrhotic rats with portal hypertension." | 3.75 | Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats. ( Alatsakis, M; Ballas, KD; Marakis, GN; Pavlidis, TE; Psarras, K; Rafailidis, S; Sakantamis, AK; Tzioufa-Asimakopoulou, V, 2009) |
| "In an effort to develop a reproducible model of liver cirrhosis and esophageal varices, we administered phenobarbital (PhB) and carbon tetrachloride (CCl4) in 32 rats that had previously undergone complete devascularization of the left renal vein (DLRV)." | 3.71 | A rat model of liver cirrhosis and esophageal varices. ( Alatsakis, MB; Ballas, KD; Sakadamis, AK; Tzioufa-Asimakopoulou, V, 2001) |
| "The present study investigated whether, in rats with portal hypertension due to cirrhosis of the liver induced by carbon tetrachloride, blood volume restitution following a hemorrhage produces an increase of portal pressure beyond control values, as observed in rats with prehepatic portal hypertension." | 3.67 | Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting. ( Arderiu, M; Bosch, J; Kravetz, D; Pilar Pizcueta, M; Rodés, J, 1989) |
| "Portal hypertension is a severe complication caused by various chronic liver diseases." | 1.56 | Assessment of a biofluid mechanics-based model for calculating portal pressure in canines. ( Deng, WS; Lin, JY; Luo, M; Song, CL; Sun, LC; Wu, LZ; Zhang, CH; Zheng, L; Zhu, YM, 2020) |
| "In conclusion, carvedilol may alleviate liver cirrhosis in rats by inhibiting HSC activation, proliferation, invasion and collagen synthesis." | 1.51 | Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis. ( Li, G; Li, Z; Ling, L; Meng, D; Wang, G; Zhang, C, 2019) |
| "Portal hypertension is a frequent pathological symptom occurring especially in hepatic fibrosis and cirrhosis." | 1.46 | Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction. ( Lu, C; Shao, J; Xu, W; Yao, S; Zhang, F; Zheng, S, 2017) |
| " The underlying mechanisms may relate to rescue NO bioavailability from macrophage-derived peroxynitrite in portal triads." | 1.39 | Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis. ( Cai, DY; Deng, B; Liu, XT; Song, YJ; Wang, YQ; Xu, XY; Yang, SJ; Zhang, T; Zhao, X, 2013) |
| "We also evaluated liver fibrosis by Sirius Red staining of liver sections, collagen-1, NFκB, TGFβ mRNA expression, and desmin and α-smooth muscle actin (α-SMA) protein expression, as a surrogate of hepatic stellate cell activation." | 1.39 | Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats. ( Bosch, J; Di Pascoli, M; Diví, M; García-Pagán, JC; Gracia-Sancho, J; Rodríguez-Vilarrupla, A; Rosado, E; Vilaseca, M, 2013) |
| " Nitric oxide (NO) bioavailability and eNOS activation were measured in hepatic endothelial cells (HEC) isolated from cirrhotic rat livers." | 1.38 | PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats. ( Bosch, J; García-Calderó, H; García-Pagán, JC; Laviña, B; Rodríguez-Vilarrupla, A; Roglans, N; Rosado, E; Russo, L, 2012) |
| "Liver cirrhosis is associated with bacterial translocation (BT) and endotoxemia." | 1.38 | Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense. ( Beisner, J; Bevins, CL; Hofmann, C; Nuding, S; Schoelmerich, J; Stange, EF; Teltschik, Z; Wehkamp, J; Wiest, R, 2012) |
| "Cirrhotic portal hypertension is characterized by mesenteric arterial vasodilation and hyporeactivity to vasoconstrictors." | 1.37 | Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. ( Angeli, P; Bolognesi, M; Calabrese, F; Di Pascoli, M; Gatta, A; Lunardi, F; Merkel, C; Pontisso, P; Sacerdoti, D; Turato, C; Verardo, A; Zampieri, F, 2011) |
| "These models represent, respectively, a secondary biliary cirrhosis and alcoholic cirrhosis." | 1.35 | Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation. ( Colle, I; De Vos, M; Geerts, AM; Praet, M; Van Vlierberghe, H; Vanheule, E, 2008) |
| " NO scavenging by superoxide (O(2)(-)) further contributes to a reduction of NO bioavailability in cirrhotic livers." | 1.35 | Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension. ( Bosch, J; Chu, Y; García-Pagán, JC; Gracia-Sancho, J; Heistad, DD; Laviña, B; Rodríguez-Vilarrupla, A, 2009) |
| "Portal hypertension is triggered by vasodilation due to impaired contraction of extrahepatic vessels." | 1.35 | Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis. ( Heller, J; Hennenberg, M; Kohistani, AZ; Sauerbruch, T; Trebicka, J, 2009) |
| "Portal hypertension is a hemodynamic syndrome due to pathological increase in portal flow and portal pressure." | 1.35 | Combined use of propranolol and nifedipine offers better effects on portal vein nonuniform remodeling in carbon tetrachloride (CCl(4))-induced portal hypertensive rats. ( Jiang, ZL; Qin, KR; Shi, B; Wu, GQ; Zhang, ZQ; Zhu, L, 2009) |
| "A model of liver cirrhosis was replicated in rats by intra-peritoneal injection of CCl4 for 8 wk." | 1.33 | Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis. ( Feng, YY; Han, J; Lu, YY; Ma, XM; Su, SH; Wang, CP; Xiang, Y; Yang, YP, 2006) |
| "Hepatic cirrhosis was induced in male Sprague-Dawley rats by intraperitoneal injection of carbon tetrachloride, and the cirrhotic rats were divided into three groups:Liposome-pcDNA(3)/iNOS (n = 10), Tris buffer (n = 10) and nude plasmid (n = 10), which were injected into the portal vein of experiment cirrhotic rats respectively." | 1.32 | [Experimental study on iNOS gene transfer mediated by liposome to treat portal hypertension in cirrhotic rats]. ( Luo, HF; Qiu, JF; Wu, ZY; Zhang, ZQ, 2004) |
| "Portal hypertension was successfully induced in 15 dogs." | 1.32 | [Morphology of portal hypertension at the early stage of liver damage induced by CCl4: an experimental study with dogs]. ( Wei, YW; Xue, DB; Zhang, RP; Zhang, WH, 2004) |
| "To assess the effects of the early and chronic administration of losartan--a specific angiotensin II receptor antagonist--in the prevention of hepatic fibrosis and portal hypertension." | 1.31 | Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension. ( Calès, P; Chappard, D; Croquet, V; Douay, O; Gallois, Y; Moal, F; Oberti, F; Roux, J; Veal, N; Vuillemin, E; Wang, J, 2002) |
| "Liver cirrhosis was induced by an intraperitoneal injection of 50% CCl(4) (0." | 1.31 | [Effects of ET-1 on isolated perfused rat liver and vascular rings at two stages of cirrhosis]. ( Fang, H; Feng, Z; Gao, J; Yang, C; Yao, D; Yao, X, 2002) |
| " Chronic administration of CCl(4) (10 weeks) induced a cirrhotic state, characterized by increased liver fibronectin and collagen types I and III content, enhanced expression of alpha-1 (I) collagen mRNA, portal hypertension, and liver dysfunction." | 1.31 | Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats. ( De Sánchez, VC; Díaz-Muñoz, M; Hernández-Muñoz, R; López, V; Sánchez-Sevilla, L; Suárez-Cuenca, JA; Trejo-Solís, C; Yáñez, L, 2001) |
| " This study investigated the effects of chronic administration of octreotide on systemic and portal haemodynamics and the development of portal hypertensive gastropathy in carbon tetrachloride-induced cirrhotic rats." | 1.30 | Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis. ( Chan, CC; Chang, FY; Chu, CJ; Lee, FY; Lee, SD; Lin, HC; Lin, HJ; Tai, CC; Wang, SS; Wu, SL, 1998) |
| "Since portal hypertension affects the gastric mucosa, leading to congestive gastropathy and thus to increased incidence of bleeding, it is one of the possible causes of increased permeability of gastric mucosal capillaries." | 1.29 | Increased capillary endothelial leakage in portal hypertensive gastric mucosa: fluorescence microscopy in CCl4-induced cirrhotic rats. ( Aletras, H; Eleftheriadis, E; Karkavelas, G; Kotzampassi, K; Papadimitriou, C, 1995) |
| " This increase was abolished by chronic administration of N(omega)-nitro-L-arginine methyl ester." | 1.29 | Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats. ( Ginés, P; Martin, PY; McMurtry, I; Morris, K; Niederberger, M; Schrier, RW; Tsai, P, 1996) |
| " On the other hand, the initial decrease in portal pressure was augmented in rats with partial portal vein ligation, and disappeared at higher dosage in CCl4-treated rats." | 1.28 | Effects of endothelin in portal hypertensive rats. ( Kuo, JS; Lin, HC; Yang, MC; Yu, PC, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (7.87) | 18.7374 |
| 1990's | 17 (19.10) | 18.2507 |
| 2000's | 31 (34.83) | 29.6817 |
| 2010's | 30 (33.71) | 24.3611 |
| 2020's | 4 (4.49) | 2.80 |
| Authors | Studies |
|---|---|
| Lafoz, E | 1 |
| Campreciós, G | 1 |
| García-Calderó, H | 3 |
| Anton, A | 1 |
| Vilaseca, M | 2 |
| Ruart, M | 1 |
| Guasch, E | 1 |
| Garrabou, G | 1 |
| Delgado, TC | 1 |
| Martínez-Chantar, ML | 1 |
| García-Martínez, R | 1 |
| Gracia-Sancho, J | 4 |
| Hernández-Gea, V | 1 |
| García-Pagán, JC | 6 |
| Rampa, DR | 2 |
| Feng, H | 2 |
| Allur-Subramaniyan, S | 2 |
| Shim, K | 2 |
| Pekcec, A | 2 |
| Lee, D | 2 |
| Doods, H | 2 |
| Wu, D | 2 |
| Zhang, B | 2 |
| Ji, LH | 1 |
| Zhang, CG | 2 |
| Zhao, G | 2 |
| Wu, ZY | 3 |
| Lin, JY | 2 |
| Zhang, CH | 2 |
| Zheng, L | 3 |
| Song, CL | 1 |
| Deng, WS | 3 |
| Zhu, YM | 2 |
| Wu, LZ | 1 |
| Sun, LC | 1 |
| Luo, M | 3 |
| Chen, J | 1 |
| Argemi, J | 1 |
| Odena, G | 1 |
| Xu, MJ | 1 |
| Cai, Y | 1 |
| Massey, V | 1 |
| Parrish, A | 1 |
| Vadigepalli, R | 1 |
| Altamirano, J | 1 |
| Cabezas, J | 1 |
| Gines, P | 2 |
| Caballeria, J | 1 |
| Snider, N | 1 |
| Sancho-Bru, P | 1 |
| Akira, S | 1 |
| Rusyn, I | 1 |
| Gao, B | 1 |
| Bataller, R | 1 |
| Klein, S | 2 |
| Schierwagen, R | 2 |
| Uschner, FE | 2 |
| Trebicka, J | 3 |
| Gui, L | 1 |
| Brückner, S | 1 |
| Zipprich, A | 1 |
| Hempel, M | 1 |
| Thonig, A | 1 |
| Schwill, F | 1 |
| Roderfeld, M | 1 |
| Roeb, E | 1 |
| Christ, B | 1 |
| Ling, L | 1 |
| Li, G | 1 |
| Wang, G | 1 |
| Meng, D | 1 |
| Li, Z | 2 |
| Zhang, C | 1 |
| Fallowfield, JA | 1 |
| Hayden, AL | 1 |
| Snowdon, VK | 1 |
| Aucott, RL | 1 |
| Stutchfield, BM | 1 |
| Mole, DJ | 1 |
| Pellicoro, A | 1 |
| Gordon-Walker, TT | 1 |
| Henke, A | 1 |
| Schrader, J | 1 |
| Trivedi, PJ | 1 |
| Princivalle, M | 1 |
| Forbes, SJ | 1 |
| Collins, JE | 1 |
| Iredale, JP | 1 |
| Zhao, X | 1 |
| Deng, B | 1 |
| Xu, XY | 1 |
| Yang, SJ | 1 |
| Zhang, T | 1 |
| Song, YJ | 1 |
| Liu, XT | 1 |
| Wang, YQ | 1 |
| Cai, DY | 1 |
| Deng, G | 2 |
| Huang, XJ | 1 |
| Luo, HW | 1 |
| Huang, FZ | 2 |
| Liu, XY | 2 |
| Wang, YH | 1 |
| Li, B | 2 |
| Shao, Q | 2 |
| Ji, D | 2 |
| Li, F | 2 |
| Chen, G | 2 |
| Zhai, L | 1 |
| Qiu, LY | 1 |
| Zu, Y | 1 |
| Yan, Y | 1 |
| Ren, XZ | 1 |
| Zhao, JF | 1 |
| Liu, YJ | 1 |
| Liu, JB | 1 |
| Qian, LX | 1 |
| Zhao, TY | 1 |
| Su, LP | 1 |
| Ma, CY | 1 |
| Zhai, XH | 1 |
| Duan, ZJ | 1 |
| Zhu, Y | 1 |
| Li, CY | 1 |
| Wang, LX | 1 |
| Yang, D | 1 |
| Rick, J | 1 |
| Lehmann, J | 1 |
| Schierwagen, IG | 1 |
| Verbeke, L | 1 |
| Hittatiya, K | 1 |
| Manekeller, S | 1 |
| Strassburg, CP | 1 |
| Wagner, KU | 1 |
| Sayeski, PP | 1 |
| Wolf, D | 1 |
| Laleman, W | 1 |
| Sauerbruch, T | 2 |
| Duan, M | 2 |
| Chen, W | 1 |
| Xu, W | 1 |
| Lu, C | 1 |
| Zhang, F | 1 |
| Shao, J | 1 |
| Yao, S | 1 |
| Zheng, S | 1 |
| Qin, J | 1 |
| He, Y | 1 |
| Matei, V | 1 |
| Rodríguez-Vilarrupla, A | 6 |
| Deulofeu, R | 1 |
| Fernández, M | 2 |
| Bosch, J | 8 |
| Geerts, AM | 1 |
| Vanheule, E | 1 |
| Praet, M | 1 |
| Van Vlierberghe, H | 2 |
| De Vos, M | 1 |
| Colle, I | 2 |
| Laviña, B | 2 |
| Chu, Y | 1 |
| Heistad, DD | 1 |
| Alatsakis, M | 1 |
| Ballas, KD | 2 |
| Pavlidis, TE | 1 |
| Psarras, K | 1 |
| Rafailidis, S | 1 |
| Tzioufa-Asimakopoulou, V | 2 |
| Marakis, GN | 1 |
| Sakantamis, AK | 1 |
| Zhang, ZQ | 2 |
| Shi, B | 1 |
| Wu, GQ | 1 |
| Qin, KR | 1 |
| Jiang, ZL | 1 |
| Zhu, L | 1 |
| Renga, B | 1 |
| Mencarelli, A | 2 |
| Migliorati, M | 1 |
| Distrutti, E | 1 |
| Fiorucci, S | 2 |
| Hong, JJ | 1 |
| Pan, FY | 1 |
| Qian, Y | 1 |
| Cheng, LC | 1 |
| Zhang, HX | 1 |
| Xue, B | 1 |
| Li, CJ | 1 |
| Hennenberg, M | 1 |
| Kohistani, AZ | 1 |
| Heller, J | 1 |
| Theodorakis, NG | 1 |
| Wang, YN | 1 |
| Wu, JM | 1 |
| Maluccio, MA | 1 |
| Sitzmann, JV | 2 |
| Skill, NJ | 1 |
| Resch, M | 1 |
| Wiest, R | 3 |
| Moleda, L | 2 |
| Fredersdorf, S | 1 |
| Stoelcker, B | 1 |
| Schroeder, JA | 1 |
| Schölmerich, J | 1 |
| Endemann, DH | 1 |
| Domenicali, M | 1 |
| Caraceni, P | 1 |
| Giannone, F | 1 |
| Baldassarre, M | 1 |
| Lucchetti, G | 1 |
| Quarta, C | 1 |
| Patti, C | 1 |
| Catani, L | 1 |
| Nanni, C | 1 |
| Lemoli, RM | 1 |
| Bernardi, M | 1 |
| Van Steenkiste, C | 1 |
| Trachet, B | 1 |
| Casteleyn, C | 1 |
| van Loo, D | 1 |
| Van Hoorebeke, L | 1 |
| Segers, P | 1 |
| Geerts, A | 1 |
| Bolognesi, M | 2 |
| Zampieri, F | 1 |
| Di Pascoli, M | 2 |
| Verardo, A | 1 |
| Turato, C | 1 |
| Calabrese, F | 1 |
| Lunardi, F | 1 |
| Pontisso, P | 1 |
| Angeli, P | 1 |
| Merkel, C | 1 |
| Gatta, A | 2 |
| Sacerdoti, D | 2 |
| Jiang, H | 2 |
| Gaiani, S | 1 |
| McGiff, JC | 1 |
| Tan, G | 1 |
| Pan, S | 1 |
| Li, J | 1 |
| Dong, X | 1 |
| Kang, K | 1 |
| Zhao, M | 1 |
| Jiang, X | 1 |
| Kanwar, JR | 1 |
| Qiao, H | 1 |
| Sun, X | 1 |
| Teltschik, Z | 1 |
| Beisner, J | 1 |
| Nuding, S | 1 |
| Hofmann, C | 1 |
| Schoelmerich, J | 1 |
| Bevins, CL | 1 |
| Stange, EF | 1 |
| Wehkamp, J | 1 |
| He, XJ | 1 |
| Huang, TZ | 1 |
| Wang, PJ | 1 |
| Peng, XC | 1 |
| Li, WC | 1 |
| Wang, J | 2 |
| Tang, J | 1 |
| Feng, N | 1 |
| Yu, MH | 1 |
| Russo, L | 1 |
| Rosado, E | 3 |
| Roglans, N | 1 |
| Coll, M | 2 |
| Rodriguez, S | 1 |
| Raurell, I | 2 |
| Ezkurdia, N | 1 |
| Brull, A | 1 |
| Augustin, S | 1 |
| Guardia, J | 3 |
| Esteban, R | 3 |
| Martell, M | 2 |
| Genescà, J | 2 |
| Sakamoto, M | 1 |
| Nakamura, T | 1 |
| Torimura, T | 1 |
| Iwamoto, H | 1 |
| Masuda, H | 1 |
| Koga, H | 1 |
| Abe, M | 1 |
| Hashimoto, O | 1 |
| Ueno, T | 1 |
| Sata, M | 1 |
| Guillaume, M | 1 |
| Mancini, A | 1 |
| Dietrich, P | 1 |
| Kees, F | 1 |
| Müller, M | 1 |
| Straub, RH | 1 |
| Hellerbrand, C | 1 |
| Liu, CH | 1 |
| Huang, XT | 1 |
| Li, YY | 1 |
| Zheng, X | 1 |
| Li, N | 1 |
| Mi, SQ | 1 |
| Wang, NS | 1 |
| Diví, M | 1 |
| Reboredo, M | 1 |
| Chang, HC | 1 |
| Barbero, R | 1 |
| Rodríguez-Ortigosa, CM | 1 |
| Pérez-Vizcaíno, F | 1 |
| Morán, A | 1 |
| García, M | 1 |
| Banales, JM | 1 |
| Carreño, N | 1 |
| Alegre, F | 1 |
| Herrero, I | 1 |
| Quiroga, J | 1 |
| Prieto, J | 1 |
| Sangro, B | 1 |
| Croquet, V | 1 |
| Moal, F | 2 |
| Veal, N | 2 |
| Oberti, F | 2 |
| Roux, J | 1 |
| Vuillemin, E | 2 |
| Gallois, Y | 1 |
| Douay, O | 1 |
| Chappard, D | 1 |
| Calès, P | 2 |
| Chiva, M | 1 |
| Guarner, C | 1 |
| Peralta, C | 1 |
| Llovet, T | 1 |
| Gómez, G | 1 |
| Soriano, G | 1 |
| Balanzó, J | 1 |
| Yao, D | 1 |
| Yao, X | 1 |
| Yang, C | 1 |
| Feng, Z | 1 |
| Fang, H | 1 |
| Gao, J | 1 |
| van der Merwe, SW | 1 |
| van den Bogaerde, JB | 1 |
| Goosen, C | 1 |
| Maree, FF | 1 |
| Milner, RJ | 1 |
| Schnitzler, CM | 1 |
| Biscardi, A | 1 |
| Mesquita, JM | 1 |
| Engelbrecht, G | 1 |
| Kahn, D | 1 |
| Fevery, J | 1 |
| Wang, H | 1 |
| Chen, XP | 1 |
| Qiu, FZ | 1 |
| Qiu, JF | 1 |
| Luo, HF | 1 |
| Thirunavukkarasu, C | 1 |
| Yang, Y | 1 |
| Subbotin, VM | 2 |
| Harvey, SA | 1 |
| Fung, J | 1 |
| Gandhi, CR | 2 |
| Zhang, RP | 1 |
| Zhang, WH | 1 |
| Xue, DB | 1 |
| Wei, YW | 1 |
| Sansoè, G | 1 |
| Aragno, M | 1 |
| Mastrocola, R | 1 |
| Restivo, F | 1 |
| Mengozzi, G | 1 |
| Smedile, A | 1 |
| Rosina, F | 1 |
| Danni, O | 1 |
| Parola, M | 1 |
| Rizzetto, M | 1 |
| Wang, CP | 2 |
| Han, J | 2 |
| Ma, XM | 2 |
| Dong, K | 1 |
| Xiang, Y | 2 |
| Su, SH | 2 |
| Feng, YY | 2 |
| Yang, YP | 2 |
| Yao, GX | 1 |
| Shen, ZY | 1 |
| Xue, XB | 1 |
| Yang, Z | 1 |
| Lu, YY | 1 |
| Luo, CQ | 1 |
| Mejías, M | 1 |
| Otero, T | 1 |
| Oria, M | 1 |
| Burns, RC | 1 |
| Wu, Y | 1 |
| Gomis, R | 1 |
| Fernández-Alvarez, J | 1 |
| Pizcueta, P | 1 |
| Casamitjana, R | 1 |
| Rodés, J | 2 |
| Kotzampassi, K | 2 |
| Karkavelas, G | 1 |
| Eleftheriadis, E | 2 |
| Papadimitriou, C | 1 |
| Aletras, H | 1 |
| Zhang, Y | 1 |
| Qi, G | 1 |
| Lui, J | 1 |
| Niederberger, M | 1 |
| Martin, PY | 1 |
| Tsai, P | 1 |
| Morris, K | 1 |
| McMurtry, I | 1 |
| Schrier, RW | 1 |
| Bozkurt, S | 1 |
| Ersoy, E | 1 |
| Tekýn, HE | 1 |
| Bayram, O | 1 |
| Anadol, Z | 1 |
| Onuk, E | 1 |
| Ercan, ZS | 1 |
| López-Talavera, JC | 1 |
| Levitzki, A | 1 |
| Martínez, M | 1 |
| Gazit, A | 1 |
| Rockey, DC | 1 |
| Chung, JJ | 1 |
| Nemoto, EM | 1 |
| Watkins, SC | 1 |
| Chan, CC | 1 |
| Lee, FY | 1 |
| Wang, SS | 1 |
| Chang, FY | 1 |
| Lin, HC | 2 |
| Lin, HJ | 1 |
| Chu, CJ | 1 |
| Wu, SL | 1 |
| Tai, CC | 1 |
| Lee, SD | 1 |
| Petrowsky, H | 1 |
| Schmandra, T | 1 |
| Lorey, T | 1 |
| Hanisch, E | 1 |
| Herrmann, G | 1 |
| Fort, J | 1 |
| Kaassis, M | 1 |
| Pilette, C | 1 |
| Loureiro-Silva, MR | 1 |
| Molina, HM | 1 |
| Borges, DR | 1 |
| Sakadamis, AK | 1 |
| Alatsakis, MB | 1 |
| Antonelli, E | 1 |
| Morelli, O | 1 |
| Casini, A | 1 |
| Mello, T | 1 |
| Palazzetti, B | 1 |
| Tallet, D | 1 |
| del Soldato, P | 1 |
| Morelli, A | 1 |
| Van de Casteele, M | 1 |
| Sägesser, H | 1 |
| Zimmermann, H | 1 |
| Reichen, J | 1 |
| Hernández-Muñoz, R | 1 |
| Díaz-Muñoz, M | 1 |
| Suárez-Cuenca, JA | 1 |
| Trejo-Solís, C | 1 |
| López, V | 1 |
| Sánchez-Sevilla, L | 1 |
| Yáñez, L | 1 |
| De Sánchez, VC | 1 |
| Wu, Z | 1 |
| Zhou, J | 1 |
| Chen, Z | 1 |
| Zhou, H | 1 |
| Jiao, Z | 1 |
| Kuang, Y | 1 |
| Yuan, J | 1 |
| Wang, Q | 1 |
| Zeng, M | 1 |
| Yu, PC | 1 |
| Kuo, JS | 1 |
| Yang, MC | 1 |
| Chen, S | 1 |
| Blendis, LM | 1 |
| Dagenais, M | 1 |
| Giroux, L | 1 |
| Belgiorno, J | 1 |
| Huet, PM | 1 |
| Miura, S | 1 |
| Serizawa, H | 1 |
| Hamada, Y | 1 |
| Tanaka, S | 1 |
| Yoshioka, M | 1 |
| Hibi, T | 1 |
| Tsuchiya, M | 1 |
| Kravetz, D | 1 |
| Arderiu, M | 1 |
| Pilar Pizcueta, M | 1 |
| Baddeley, RM | 2 |
| Ejr, SJ | 1 |
| Evans, J | 1 |
| McLean, EK | 2 |
| McLean, AE | 1 |
| Sutton, PM | 1 |
| Banerjee, AK | 1 |
| Aikat, BK | 1 |
| Hill, KR | 1 |
| Fejfar, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Serelaxin To Lower Portal Pressure in Patients With Cirrhosis and Portal Hypertension[NCT02669875] | Phase 2 | 15 participants (Actual) | Interventional | 2017-10-18 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for carbon tetrachloride and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow.
Topics: Animals; Ascites; Bile Ducts; Blood Flow Velocity; Carbon Tetrachloride; Disease Models, Animal; Hem | 2001 |
Hepatocyte swelling and portal hypertension.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Hepatomegaly; Hypertension, Portal; Liver; Li | 1992 |
87 other studies available for carbon tetrachloride and Cruveilhier-Baumgarten Syndrome
| Article | Year |
|---|---|
Impact of lifestyle interventions targeting physical exercise and caloric intake on cirrhosis regression in rats.
Topics: Animals; Caloric Restriction; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury; Energy I | 2021 |
Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice.
Topics: Animals; Carbon Tetrachloride; Fibrosis; Hepatic Stellate Cells; Humans; Hypertension, Portal; Kinin | 2022 |
Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice.
Topics: Animals; Carbon Tetrachloride; Fibrosis; Hepatic Stellate Cells; Humans; Hypertension, Portal; Kinin | 2022 |
Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice.
Topics: Animals; Carbon Tetrachloride; Fibrosis; Hepatic Stellate Cells; Humans; Hypertension, Portal; Kinin | 2022 |
Kinin B1 receptor blockade attenuates hepatic fibrosis and portal hypertension in chronic liver diseases in mice.
Topics: Animals; Carbon Tetrachloride; Fibrosis; Hepatic Stellate Cells; Humans; Hypertension, Portal; Kinin | 2022 |
Gender differences in vascular reactivity of mesenteric arterioles in portal hypertensive and non-portal hypertensive rats.
Topics: Animals; Arterioles; Carbon Tetrachloride; Female; Gonadal Steroid Hormones; Humans; Hypertension, P | 2019 |
Assessment of a biofluid mechanics-based model for calculating portal pressure in canines.
Topics: Animals; Biomechanical Phenomena; Blood Flow Velocity; Carbon Tetrachloride; Dog Diseases; Dogs; Hyp | 2020 |
Hepatic lipocalin 2 promotes liver fibrosis and portal hypertension.
Topics: Animals; Carbon Tetrachloride; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Anim | 2020 |
Mouse and Rat Models of Induction of Hepatic Fibrosis and Assessment of Portal Hypertension.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Hemodynamics; Hypertension, Portal; Liver Cir | 2017 |
Soluble epoxide hydrolase inhibition with t-TUCB alleviates liver fibrosis and portal pressure in carbon tetrachloride-induced cirrhosis in rats.
Topics: Animals; Benzoates; Carbon Tetrachloride; Disease Models, Animal; Epoxide Hydrolases; Hypertension, | 2018 |
Improvement of portal venous pressure in cirrhotic rat livers by systemic treatment with adipose tissue-derived mesenchymal stromal cells.
Topics: Adipose Tissue; Animals; Carbon Tetrachloride; Cell Differentiation; Collagen; Disease Models, Anima | 2017 |
Carvedilol improves liver cirrhosis in rats by inhibiting hepatic stellate cell activation, proliferation, invasion and collagen synthesis.
Topics: Administration, Oral; Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Carb | 2019 |
Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo.
Topics: Actins; Animals; Carbon Tetrachloride; Cells, Cultured; Desmin; Disease Models, Animal; Glial Fibril | 2014 |
Glycyrrhizinate reduces portal hypertension in isolated perfused rat livers with chronic hepatitis.
Topics: Animals; Antihypertensive Agents; Carbon Tetrachloride; Chemical and Drug Induced Liver Injury, Chro | 2013 |
Amelioration of carbon tetrachloride-induced cirrhosis and portal hypertension in rat using adenoviral gene transfer of Akt.
Topics: Adenoviridae; Animals; Apoptosis; Apoptosis Regulatory Proteins; Carbon Tetrachloride; Disease Model | 2013 |
Mesenchymal stem cells mitigate cirrhosis through BMP7.
Topics: Animals; Bone Morphogenetic Protein 7; Carbon Tetrachloride; Cells, Cultured; Gene Expression Regula | 2015 |
Contrast-enhanced ultrasound for quantitative assessment of portal pressure in canine liver fibrosis.
Topics: Animals; Area Under Curve; Biopsy; Blood Flow Velocity; Blood Pressure Determination; Carbon Tetrach | 2015 |
MiR-22 Suppresses BMP7 in the Development of Cirrhosis.
Topics: 3' Untranslated Regions; Adult; Animals; Bone Morphogenetic Protein 7; Carbon Tetrachloride; Dependo | 2015 |
IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats.
Topics: Animals; Apoptosis; Caco-2 Cells; Carbon Tetrachloride; Claudin-1; Endotoxins; Humans; Hypertension, | 2015 |
Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis.
Topics: Adult; Animals; Carbon Tetrachloride; Collagen; Enzyme Inhibitors; Female; Hepatic Stellate Cells; H | 2017 |
Role of estrogen receptor β selective agonist in ameliorating portal hypertension in rats with CCl4-induced liver cirrhosis.
Topics: Actins; Animals; Carbon Tetrachloride; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cycl | 2016 |
Dihydroartemisinin counteracts fibrotic portal hypertension via farnesoid X receptor-dependent inhibition of hepatic stellate cell contraction.
Topics: Animals; Artemisinins; Carbon Tetrachloride; Cell Death; Chenodeoxycholic Acid; Gene Expression; Hep | 2017 |
Effects of Nuclear Factor-E2-related factor 2/Heme Oxygenase 1 on splanchnic hemodynamics in experimental cirrhosis with portal hypertension.
Topics: Animals; Arterioles; Carbon Tetrachloride; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); Hemodyna | 2017 |
Three-day tetrahydrobiopterin therapy increases in vivo hepatic NOS activity and reduces portal pressure in CCl4 cirrhotic rats.
Topics: Animals; Biopterins; Carbon Tetrachloride; Cyclic GMP; Enzyme Inhibitors; Hypertension, Portal; Hypo | 2008 |
Comparison of three research models of portal hypertension in mice: macroscopic, histological and portal pressure evaluation.
Topics: Animals; Ascites; Carbon Tetrachloride; Common Bile Duct; Disease Progression; Hypertension, Portal; | 2008 |
Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension.
Topics: Adenoviridae; Animals; Carbon Tetrachloride; Endothelium, Vascular; Gene Transfer Techniques; Geneti | 2009 |
Early propranolol administration does not prevent development of esophageal varices in cirrhotic rats.
Topics: Animals; Carbon Tetrachloride; Esophageal and Gastric Varices; Hypertension, Portal; Liver Cirrhosis | 2009 |
Combined use of propranolol and nifedipine offers better effects on portal vein nonuniform remodeling in carbon tetrachloride (CCl(4))-induced portal hypertensive rats.
Topics: Adrenergic beta-Antagonists; Animals; Calcium Channel Blockers; Carbon Tetrachloride; Drug Combinati | 2009 |
Bile-acid-activated farnesoid X receptor regulates hydrogen sulfide production and hepatic microcirculation.
Topics: Adrenergic alpha-Agonists; Animals; Base Sequence; Bile Acids and Salts; Carbon Tetrachloride; Cell | 2009 |
Overexpression of beta-catenin is responsible for the development of portal hypertension during liver cirrhosis.
Topics: Adenoviridae; Animals; beta Catenin; Carbon Tetrachloride; Disease Models, Animal; Disease Progressi | 2009 |
Vascular hyporesponsiveness to angiotensin II in rats with CCl(4)-induced liver cirrhosis.
Topics: Angiotensin II; Animals; Aorta; Blotting, Western; Carbon Tetrachloride; Hypertension, Portal; Liver | 2009 |
Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
Topics: Alanine Transaminase; Animals; Aorta, Abdominal; Carbon Tetrachloride; Genotype; Hyperemia; Hyperten | 2009 |
Alterations in mechanical properties of mesenteric resistance arteries in experimental portal hypertension.
Topics: Animals; Biomechanical Phenomena; Blood Pressure; Carbon Tetrachloride; Elasticity; Hypertension, Po | 2009 |
A novel model of CCl4-induced cirrhosis with ascites in the mouse.
Topics: Administration, Inhalation; Animals; Ascites; Carbon Tetrachloride; Cytokines; Disease Models, Anima | 2009 |
Vascular corrosion casting: analyzing wall shear stress in the portal vein and vascular abnormalities in portal hypertensive and cirrhotic rodents.
Topics: Animals; Carbon Tetrachloride; Corrosion Casting; Hypertension, Portal; Liver; Liver Cirrhosis, Expe | 2010 |
Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats.
Topics: 8,11,14-Eicosatrienoic Acid; Acetylcholine; Analysis of Variance; Animals; Carbon Tetrachloride; Con | 2011 |
11,12-EET increases porto-sinusoidal resistance and may play a role in endothelial dysfunction of portal hypertension.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Carbon Tetrachloride; Cytochrome P-450 Enzym | 2011 |
Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats.
Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Blood Pressure; Carbon Tetrachloride; Cy | 2011 |
Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense.
Topics: Animals; Bacterial Translocation; Bacteroides fragilis; beta-Defensins; Bifidobacterium; Carbon Tetr | 2012 |
Morphological and biomechanical remodeling of the hepatic portal vein in a swine model of portal hypertension.
Topics: Animals; Biomechanical Phenomena; Carbon Tetrachloride; Compliance; Down-Regulation; Elastic Modulus | 2012 |
PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.
Topics: Animals; Blood Pressure; Carbon Tetrachloride; Cyclooxygenase 1; Disease Models, Animal; Endothelium | 2012 |
Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats.
Topics: Animals; Antiparkinson Agents; Bile Ducts; Blood Pressure; Carbidopa; Carbon Tetrachloride; Disease | 2012 |
Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model.
Topics: Animals; Blood Vessels; Carbon Tetrachloride; Caveolins; Cell Proliferation; Endothelial Cells; Endo | 2013 |
Recombinant human manganese superoxide dismutase reduces liver fibrosis and portal pressure in CCl4-cirrhotic rats.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Hypertension, Portal; Liver Cirrhosis; Male; | 2013 |
Dysbalance in sympathetic neurotransmitter release and action in cirrhotic rats: impact of exogenous neuropeptide Y.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Electric Stimulation; Hypertension, Portal; L | 2013 |
[The anti-portal hypertension effect of oleanolic acid in CCl4-induced cirrhosis rats].
Topics: Animals; Body Weight; Carbon Tetrachloride; Disease Models, Animal; Hypertension, Portal; Liver; Liv | 2012 |
Resveratrol improves intrahepatic endothelial dysfunction and reduces hepatic fibrosis and portal pressure in cirrhotic rats.
Topics: Animals; Antioxidants; Carbon Tetrachloride; Disease Models, Animal; Dose-Response Relationship, Dru | 2013 |
Zolmitriptan: a novel portal hypotensive agent which synergizes with propranolol in lowering portal pressure.
Topics: Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Body Weight; Carbon Tetrachloride; Ca | 2013 |
Hemodynamic and antifibrotic effects of losartan in rats with liver fibrosis and/or portal hypertension.
Topics: Alanine Transaminase; Alkaline Phosphatase; Angiotensin Receptor Antagonists; Animals; Bile Ducts; B | 2002 |
Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats.
Topics: Animals; Bacterial Translocation; Biomarkers; Carbon Tetrachloride; Cecum; Enterococcus faecalis; En | 2003 |
[Effects of ET-1 on isolated perfused rat liver and vascular rings at two stages of cirrhosis].
Topics: Animals; Carbon Tetrachloride; Dose-Response Relationship, Drug; Endothelin-1; Hypertension, Portal; | 2002 |
Hepatic osteodystrophy in rats results mainly from portasystemic shunting.
Topics: Absorptiometry, Photon; Animals; Bone Density; Carbon Tetrachloride; Disease Models, Animal; Female; | 2003 |
Salviae miltiorrhizae ameliorates cirrhosis and portal hypertension by inhibiting nitric oxide in cirrhotic rats.
Topics: Animals; Carbon Tetrachloride; Drugs, Chinese Herbal; Hypertension, Portal; Liver; Liver Circulation | 2003 |
[Experimental study on iNOS gene transfer mediated by liposome to treat portal hypertension in cirrhotic rats].
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Hypertension, Portal; Immunohistochemistry; L | 2004 |
Endothelin receptor antagonist TAK-044 arrests and reverses the development of carbon tetrachloride induced cirrhosis in rats.
Topics: Animals; Carbon Tetrachloride; Disease Progression; Endothelin Receptor Antagonists; Endothelin-1; H | 2004 |
[Morphology of portal hypertension at the early stage of liver damage induced by CCl4: an experimental study with dogs].
Topics: Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Chemical and Drug Induced Liver Injur | 2004 |
Neutral endopeptidase (EC 3.4.24.11) in cirrhotic liver: a new target to treat portal hypertension?
Topics: Animals; Arginine Vasopressin; Atrial Natriuretic Factor; Blood Pressure; Carbon Tetrachloride; Cycl | 2005 |
[Influence of platelet activating factor and its antagonist on portal hypertension associated with liver cirrhosis: an experiment with rats].
Topics: Animals; Carbon Tetrachloride; Ginkgolides; Hypertension, Portal; Injections, Intravenous; Lactones; | 2005 |
Intestinal permeability in rats with CCl4-induced portal hypertension.
Topics: Animals; Carbon Tetrachloride; Endotoxins; Escherichia coli; Humans; Hypertension, Portal; Intestina | 2006 |
Effect of increased hepatic platelet activating factor and its receptor portal hypertension in CCl4-induced liver cirrhosis.
Topics: Animals; Base Sequence; Blood Pressure; Carbon Tetrachloride; Diterpenes; Ginkgolides; Hypertension, | 2006 |
[Akt gene therapy for cirrhotic rats with portal hypertension].
Topics: Adenoviridae; Animals; Carbon Tetrachloride; Carbon Tetrachloride Poisoning; Genetic Therapy; Hypert | 2008 |
Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension.
Topics: Animals; Carbon Tetrachloride; Disease Models, Animal; Dopamine beta-Hydroxylase; Down-Regulation; G | 2008 |
Role of cirrhosis in the hemodynamic response to hemorrhage in portal hypertension.
Topics: Animals; Carbon Tetrachloride; Common Bile Duct; Hemodynamics; Hemorrhage; Hypertension, Portal; Lig | 1995 |
Impaired function of pancreatic islets from rats with portal hypertension resulting from cirrhosis and partial portal vein ligation.
Topics: Animals; Carbon Tetrachloride; Glucagon; Hypertension, Portal; In Vitro Techniques; Insulin; Insulin | 1994 |
Increased capillary endothelial leakage in portal hypertensive gastric mucosa: fluorescence microscopy in CCl4-induced cirrhotic rats.
Topics: Albumins; Animals; Carbon Tetrachloride; Cell Membrane Permeability; Endothelium, Vascular; Fluoresc | 1995 |
[99mTc-MIBI used for diagnosis of portal hypertension: an experimental study].
Topics: Administration, Rectal; Animals; Carbon Tetrachloride; Heart; Hypertension, Portal; Injections, Intr | 1995 |
Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats.
Topics: Animals; Aorta; Ascites; Carbon Tetrachloride; Cyclic GMP; Hemodynamics; Hypertension, Portal; Ligat | 1996 |
The cytoprotective effect of iloprost against carbon tetrachloride induced necrosis in rat liver.
Topics: Animals; Carbon Tetrachloride; Dinoprostone; Disease Models, Animal; Female; Histamine; Hypertension | 1997 |
Tyrosine kinase inhibition ameliorates the hyperdynamic state and decreases nitric oxide production in cirrhotic rats with portal hypertension and ascites.
Topics: Animals; Ascites; Benzylidene Compounds; Carbon Tetrachloride; Enzyme Inhibitors; Hypertension, Port | 1997 |
Reduced nitric oxide production by endothelial cells in cirrhotic rat liver: endothelial dysfunction in portal hypertension.
Topics: Animals; Carbon Tetrachloride; Endothelium; Hypertension, Portal; Kupffer Cells; Ligation; Liver; Li | 1998 |
An endothelin receptor antagonist TAK-044 ameliorates carbon tetrachloride-induced acute liver injury and portal hypertension in rats.
Topics: Animals; Carbon Tetrachloride; Cells, Cultured; Endothelin Receptor Antagonists; Endothelin-1; Hyper | 1998 |
Chronic administration of octreotide ameliorates portal hypertension and portal hypertensive gastropathy in rats with cirrhosis.
Topics: Animals; Carbon Tetrachloride; Gastric Mucosa; Gastrointestinal Agents; Hypertension, Portal; Liver | 1998 |
Endothelin-induced contraction of the portal vein in cirrhosis.
Topics: Animals; Carbon Tetrachloride; Dose-Response Relationship, Drug; Endothelin-1; Endothelin-3; Hyperte | 1999 |
Spleno-renal shunt blood flow is an accurate index of collateral circulation in different models of portal hypertension and after pharmacological changes in rats.
Topics: Animals; Carbon Tetrachloride; Collateral Circulation; Dimethylnitrosamine; Disease Models, Animal; | 2000 |
Portal hypertensive response to bradykinin in inflamed or cirrhotic rat livers is mediated by B2-type receptors.
Topics: Analysis of Variance; Animals; Bradykinin; Carbon Tetrachloride; Hypertension, Portal; Inflammation; | 2001 |
A rat model of liver cirrhosis and esophageal varices.
Topics: Animals; Carbon Tetrachloride; Collateral Circulation; Disease Models, Animal; Esophageal and Gastri | 2001 |
NCX-1000, a NO-releasing derivative of ursodeoxycholic acid, selectively delivers NO to the liver and protects against development of portal hypertension.
Topics: Animals; Carbon Tetrachloride; Collagen; Hypertension, Portal; Liver; Liver Cirrhosis; Male; Nitrate | 2001 |
Adenosine reverses a preestablished CCl4-induced micronodular cirrhosis through enhancing collagenolytic activity and stimulating hepatocyte cell proliferation in rats.
Topics: Adenosine; Animals; Carbon Tetrachloride; Cell Division; Collagen; DNA; Fibronectins; Hepatocytes; H | 2001 |
[The role of nitric oxide in hyperdynamic circulation in portal hypertensive rats].
Topics: Animals; Arginine; Carbon Tetrachloride; Disease Models, Animal; Enzyme Inhibitors; Hemodynamics; Hy | 1998 |
Effects of endothelin in portal hypertensive rats.
Topics: Animals; Blood Pressure; Carbon Tetrachloride; Cardiovascular System; Dose-Response Relationship, Dr | 1992 |
[Effects of spleen on inducing portal hypertension and liver cirrhosis in rats].
Topics: Animals; Carbon Tetrachloride; Ethanol; Hypertension, Portal; Liver Cirrhosis, Experimental; Male; R | 1992 |
Gastric mucosal blood flow distribution in the CCl4-induced cirrhotic rat--a model of portal hypertensive gastropathy?
Topics: Animals; Blood Flow Velocity; Carbon Tetrachloride; Disease Models, Animal; Gastric Mucosa; Hyperten | 1992 |
The effect of alcohol-induced hepatomegaly on portal hypertension in cirrhotic rats.
Topics: Animals; Blood Pressure; Carbon Tetrachloride; Collagen; Ethanol; Hemodynamics; Hepatomegaly; Hypert | 1992 |
Alterations of intestinal lymphatic system and mucosal immunity in CCl4-induced portal hypertensive rats.
Topics: Animals; Carbon Tetrachloride; Hypertension, Portal; Intestinal Mucosa; Intestine, Small; Liver Cirr | 1989 |
Hemodynamic effects of blood volume restitution following a hemorrhage in rats with portal hypertension due to cirrhosis of the liver: influence of the extent of portal-systemic shunting.
Topics: Animals; Blood Volume; Carbon Tetrachloride; Collateral Circulation; Hemodynamics; Hemorrhage; Hyper | 1989 |
Gastric secretion in canines with cirrhosis and ascites.
Topics: Animals; Ascites; Carbon Tetrachloride; Catheterization; Dogs; Female; Gastric Juice; Gastric Mucosa | 1969 |
Instant cirrhosis. An improved method for producing cirrhosis of the liver in rats by simultaneous administration of carbon tetrachloride and phenobarbitone.
Topics: Animals; Ascites; Carbon Tetrachloride; Gases; Hypertension, Portal; Liver Cirrhosis, Experimental; | 1969 |
Effect of liver regeneration on the portal pressure and vascular pattern in normal and cirrhotic rats.
Topics: Animals; Blood Pressure Determination; Carbon Tetrachloride; Collagen; DNA; Hepatectomy; Hypertensio | 1968 |
Portal hypertension in acute experimental veno-occlusive disease of the liver in rats.
Topics: Anesthesia, Inhalation; Animals; Blood Pressure Determination; Carbon Tetrachloride; Chemical and Dr | 1969 |
A composite canine model of cirrhosis.
Topics: Animals; Ascites; Blood Pressure; Carbon Tetrachloride; Dogs; Hypertension, Portal; Liver; Liver Cir | 1969 |